Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Institute of Clinical Pharmacy, Central South University, Changsha, China.
Clin Exp Pharmacol Physiol. 2021 Feb;48(2):203-210. doi: 10.1111/1440-1681.13425. Epub 2020 Nov 7.
The coronavirus disease 2019 (COVID-19) is an epidemic disease caused by the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) and spreading throughout the world rapidly. Here we evaluated the efficacy of the Lopinavir/Ritonavir (LPV/r) and its combination with other drugs in the treatment of COVID-19. We included 170 confirmed COVID-19 patients who had been cured and discharged. Their antiviral therapies were LPV/r alone or combinations with interferon (IFN), Novaferon and Arbidol. We evaluated the medication efficacy by comparing the time of the negative nucleic acid conversion and the length of hospitalization mainly. The LPV/r + Novaferon [6.00 (4.00-8.00) and 7.50 (5.00-10.00) days] had shorter time of the negative nucleic acid conversion (P = .0036) and shorter time of hospitalization (P < .001) compared with LPV/r alone [9.00 (5.00-12.00) and 12.00 (11.00-15.00) days] and LPV/r + IFN [9.00 (7.25-11.00) and 12.00 (10.00-13.50) days]. On the contrary, LPV/r + IFN [9.00 (7.25-11.00) and 12.00 (10.00-13.50) days] had shorter time of the negative nucleic acid conversion (P = .031) and shorter time of hospitalization (P < .001) compared with LPV/r + IFN +Novaferon [10.00 (8.00-11.25) and 13.50 (11.50-17.00) days] and LPV/r + IFN +Arbidol [14.00 (9.75-19.00) and 19.50 (13.25-24.00) days]. In conclusion, the combination of LPV/r and Novaferon may have better efficacy against COVID-19. However, adding IFN based on LPV/r + Novaferon or adding Arbidol based on LPV/r + IFN may not improve the efficacy.
新型冠状病毒肺炎（COVID-19）是一种由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的传染病，在全球迅速传播。在这里，我们评估了洛匹那韦/利托那韦（LPV/r）及其与其他药物联合治疗 COVID-19 的疗效。我们纳入了 170 例已治愈出院的确诊 COVID-19 患者。他们的抗病毒治疗方案为 LPV/r 单药或联合干扰素（IFN）、诺华芬和阿比多尔。我们主要通过比较核酸转阴时间和住院时间来评估药物疗效。LPV/r + 诺华芬[6.00（4.00-8.00）和 7.50（5.00-10.00）天]的核酸转阴时间（P=0.0036）和住院时间（P<0.001）均短于 LPV/r 单药[9.00（5.00-12.00）和 12.00（11.00-15.00）天]和 LPV/r + IFN[9.00（7.25-11.00）和 12.00（10.00-13.50）天]。相反，LPV/r + IFN[9.00（7.25-11.00）和 12.00（10.00-13.50）天]的核酸转阴时间（P=0.031）和住院时间（P<0.001）均短于 LPV/r + IFN + 诺华芬[10.00（8.00-11.25）和 13.50（11.50-17.00）天]和 LPV/r + IFN + 阿比多尔[14.00（9.75-19.00）和 19.50（13.25-24.00）天]。总之，LPV/r 联合诺华芬可能对 COVID-19 有更好的疗效。然而，在 LPV/r + Novaferon 的基础上加用 IFN 或在 LPV/r + IFN 的基础上加用 Arbidol 并不能提高疗效。
